Treatment of Helminth Infections in Pregnancy
For pregnant women with confirmed helminth (worm) infections after the first trimester, albendazole or mebendazole are safe and effective treatment options, with albendazole demonstrating superior cure rates (up to 90% for hookworm and Ascaris). Treatment should be deferred until after the first trimester when possible, though severe infections may warrant earlier intervention with careful risk-benefit assessment.
Treatment Algorithm by Trimester
First Trimester
- Defer treatment until second trimester for asymptomatic or mild infections 1, 2
- For severe infections requiring immediate treatment, carefully weigh maternal risks against theoretical fetal risks
- No anthelmintic is FDA-approved for first-trimester use, though recent observational data suggest mebendazole may be used if absolutely necessary 3
Second and Third Trimesters
Preferred agents:
- Albendazole: Single 400mg dose (cure rates: 90% for hookworm and Ascaris, 50% for Trichuris) 1
- Mebendazole: 500mg single dose or 100mg twice daily for 3 days (cure rates: ≤70% for most helminths) 1, 4
Alternative agents for specific infections:
- Praziquantel: 40mg/kg single dose for schistosomiasis - recently demonstrated safe and effective in pregnancy, reducing maternal anemia 5
- Pyrantel pamoate: Can be considered, though limited pregnancy data 3
- Ivermectin: Limited data; one case report showed successful use for gnathostomiasis in pregnancy 6, but cure rates for soil-transmitted helminths are lower (29% for hookworm) 1
Key Safety Evidence
Reassuring data:
- Large randomized trial (N=1,042) showed no increased risk of miscarriage, malformations, stillbirth, or preterm delivery with mebendazole 4
- Meta-analysis of 4,265 pregnant women found no impact on low birthweight (RR 1.00), preterm birth (RR 0.88), or perinatal mortality (RR 1.09) 2
- Praziquantel trial in 165 pregnant women showed no adverse pregnancy outcomes and reduced maternal anemia at delivery (OR 0.40) 5
Important caveats:
- Observational data identified possible signals: 5 major malformations among 75 mebendazole-exposed infants (3 cardiac defects), and 2 cases of aplasia cutis congenita with pyrantel (one co-exposed to thiamazole) 3. These require further investigation but should not prevent treatment when indicated.
Clinical Indications for Treatment
Treat when:
- Confirmed hookworm infection (causes iron-deficiency anemia)
- Symptomatic infection with any helminth
- High parasite burden detected on stool examination
- Endemic areas with >20-30% hookworm prevalence (WHO recommendation)
Benefits of treatment:
- Reduces maternal anemia 5
- Decreases parasite burden and associated morbidity
- High cure rates for most soil-transmitted helminths 1
Practical Management Points
- Iron supplementation should accompany anthelmintic treatment for hookworm-associated anemia 2
- Single-dose regimens are preferred for compliance and simplicity
- Stool examination should be performed to identify specific parasites and guide drug selection
- Common adverse effects (dizziness, nausea, vomiting) are generally mild and self-limited 5
- No breastfeeding restrictions exist for these medications
What NOT to Use
- Avoid thiabendazole (more toxic alternatives available)
- Ivermectin should be reserved for specific indications where other agents are ineffective, given lower cure rates for common helminths 1
The evidence strongly supports that treating helminth infections after the first trimester improves maternal health without increasing fetal risk, making treatment the appropriate standard of care for confirmed infections 1, 4, 2, 5.